Verastem has opened its KRAS G12D colorectal cancer trial, but the real test is still ahead
Verastem has started TARGET-D 203, testing VS-7375 alone and in combinations for KRAS G12D metastatic colorectal cancer.
Pharma & Biotech
Pharma & Biotech
Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?
Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.